Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-463-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
According to a GLP study conducted in accordance with OECD Guideline 423, the oral LD50 of the test item is higher that 2000 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 30 December 2013 - 25 February 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study performed according to OECD test guideline No. 423 and in compliance with GLP.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 17 December 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- French GLP Compliance Programme for chemical products (inspected on 03-04 June 2013 / signed on 13 September 2013)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- (SPF Caw)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Elevage JANVIER LABS (53940 Le Genest St Isle – France)
- Females (if applicable) nulliparous and non-pregnant: Not specified
- Age at study initiation: 8 weeks old
- Weight at study initiation: 183 - 197 g
- Fasting period before study: food was removed at D-1 and then redistributed 4 hours after the test item administration.
- Housing: housed by group of three in solid-bottomed clear polycarbonate cages with a stainless steel mesh lid. Each cage contains sawdust bedding which was changed at least 2 times a week. Each cage was installed in conventional air conditioned animal husbandry.
- Diet (e.g. ad libitum): foodstuff (SAFE, A04), ad libitum
- Water (e.g. ad libitum): drinking water (tap-water from public distribution system), ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17 - 25 °C
- Humidity (%): 39 - 59%
- Air changes (per hr): ca. 13 changes per hour
- Photoperiod (hrs dark / hrs light): 12h light / 12h darkness
IN-LIFE DATES: From: 14 January 2014 To: 29 January 2014 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 2.14 mL/kg body weight (corresponding to 2 g/kg, according to the calculated density)
DOSAGE PREPARATION (if unusual): The test item was used as supplied in this study.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: The experimental protocol was established according to the official method as defined in the OECD guideline No. 423 dated December 17th, 2001 and the test method B.1tris of the Council regulation No. 440/2008. - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 6 females/dose (3 females for the Step 1 and 3 females for the Step 2)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days.
- Frequency of observations: Systematic examinations were carried out daily to identify any behavioural or toxic effects on the major physiological functions during 14 days following the administration of the test item. Observations and a mortality report were then carried out every day for 14 days.
- Frequency of weighing: D0 (just before administering the test item) then on D2, D7, and D14.
- Necropsy of survivors performed: Yes; On D14, the animals were anaesthetised with sodium pentobarbital and administration continued to fatal levels.
- Other examinations performed: Macroscopic observations were entered on individual autopsy sheets. Only those organs likely to be modified in cases of acute toxicity were examined. Those presenting macroscopic anomalies can be removed and preserved in view to microscopic examinations. - Statistics:
- None
- Preliminary study:
- Not applicable
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No mortality was observed.
- Mortality:
- No mortality occurred during the study.
- Clinical signs:
- other: No clinical signs related to the administration of the test item were observed during the study.
- Gross pathology:
- The macroscopic examination of the animals at the end of the study did not reveal any treatment related changes.
- Other findings:
- None
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The oral LD50 of the test substance, Terpenic Oligomers, is higher than 2000 mg/kg bw in female rats. In accordance with OECD Guideline No. 423, the LD50 cut-off of the test item may be considered to be higher than 5000 mg/kg body weight by oral route in the rat. Therefore, the test substance, Terpenic Oligomers, is not classified for acute oral toxicity according to;Regulation (EC) No 1272/2008 (CLP) and according to the GHS Regulation.
- Executive summary:
An acute oral toxicity study was performed according to OECD Guideline 423 and in compliance with GLP.
One group of three fasted female SPF Caw (SD) rats received a single oral gavage dose of the test substance at a dose level of 2000 mg/kg bw. As results at this dose level indicated the acute lethal oral dose of the test substance to be greater than 2000 mg/kg bw, in compliance with the study guidelines, a further group of three fasted females was similarly administered a dose of 2000 mg/kg bw to complete the study. Animals were then observed for mortality, clinical signs and bodyweights for 14 days and were all sacrificed for macroscopic examination.
There were no deaths during the study. No clinical signs related to the administration of the test item were observed during the study and the body weight evolution of the animals remained normal throughout the study. No abnormalities were noted in any animal at the macroscopic examination at study termination on Day 15.
Therefore, the oral LD50 of the test substance, Terpenic Oligomers, is higher than 2000 mg/kg bw in female rats. In accordance with OECD Guideline No. 423, the LD50 cut-off of the test item may be considered to be higher than 5000 mg/kg body weight by oral route in the rat. Therefore, the test substance, Terpenic Oligomers, is not classified for acute oral toxicity according to Regulation (EC) No 1272/2008 (CLP) and according to the GHS Regulation.
This study is considered as acceptable and satisfies the requirement for acute oral toxicity endpoint.
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity
A key study (Richeux, 2014, Rel. 1) was performed to assess the acute toxicity of the test substance after oral administration. This standard acute oral toxicity study was performed according to the OECD 423 Guideline under GLP compliance.
One group of three fasted female SPF Caw (SD) rats received a single oral gavage dose of the test substance at a dose level of 2000 mg/kg bw. As results at this dose level indicated the acute lethal oral dose of the test substance to be greater than 2000 mg/kg bw, in compliance with the study guidelines, a further group of three fasted females was similarly dosed at 2000 mg/kg bw to complete the study. Animals were then observed for mortality, clinical signs and bodyweights for 14 days and were all sacrificed for macroscopic examination. All animals survived, no clinical signs related to the administration of the test item were observed during the study and the body weight evolution of the animals remained normal throughout the study. No abnormalities were noted in any animal at the macroscopic examination at study termination on Day 15.
Therefore, the oral LD50 of the test substance, Terpenic Oligomers, is higher than 2000 mg/kg bw in female rats. In accordance with OECD Guideline No. 423, the LD50 cut-off of the test item may be considered to be higher than 5000 mg/kg body weight by oral route in the rat. Therefore, the test substance, Terpenic Oligomers, is not classified for acute oral toxicity according to Regulation (EC) No 1272/2008 (CLP) and according to the GHS.
This study is considered as acceptable and satisfy the requirement for acute oral toxicity endpoint.
Acute inhalation toxicity
No data was available regarding the acute toxicity assessment via inhalation route.
Acute dermal toxicity
No data was available regarding the acute toxicity assessment via dermal route.
Justification for classification or non-classification
Harmonized classification
Terpenic oligomers do not have an harmonized classification according to Regulation (EC) No. 1272/2008.
Self-classification
Acute toxicity (oral):
Based on the available information, the substance is:
- not classified according to Regulation (EC) No. 1272/2008 (CLP) as the oral LD50 is higher than 2000 mg/kg bw
- not classified according to the GHS Regulation since there is no reliable evidence that indicates the LD50 to be in the range of Category 5 values (GHS criteria not met).
Acute toxicity (Dermal):
No information was available. However, the substance is not classified for acute oral toxicity and no mortality and no clinical signs related to the substance were observed up to 2000 mg/kg bw by oral route. In addition, the substance is not soluble in water and has very high log Kow (> 5), therefore dermal absorption is expected to be very limited. In conclusion, the substance does not require classification for acute dermal toxicity and no further study is deemed necessary.
Acute toxicity (Inhalation):
No information was available. This route of exposure is not relevant to humans because the substance is not volatile (highest Vp value = 0.8 Pa at 25 °C for beta-pinene dimer) and the substance is a viscous liquid therefore exposure by inhalation is anticipated to be unlikely and no further study is deemed necessary by this route of exposure.
Specific target organ toxicity - single exposure (Oral):
The classification criteria according to Regulation (EC) No. 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral are not met since no reversible or irreversible adverse health effects were observed immediately or delayed after exposure and no effects were observed at the guidance value (oral) for a Category 1 classification (C≤ 300 mg/kg bw) and at the guidance value (oral) for a Category 2 classification (2000 mg/kg bw≥ C > 300 mg/kg bw). No classification is required.
The criteria for Transient Organ effects (STOT-SE Category 3) according to Regulation (EC) No. 1272/2008 are not met since narcotic effects were not observed in the acute oral toxicity study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.